Background-Cardiac hypertrophy is a common response to circulatory or neurohumoral stressors as a mechanism to augment contractility. When the heart is under sustained stress, the hypertrophic response can evolve into decompensated heart failure, although the mechanism(s) underlying this transition remain largely unknown. Because phosphorylation of cardiac myosin light chain 2 (MLC2v), bound to myosin at the head-rod junction, facilitates actin-myosin interactions and enhances contractility, we hypothesized that phosphorylation of MLC2v plays a role in the adaptation of the heart to stress. We previously identified an enzyme that predominantly phosphorylates MLC2v in cardiomyocytes, cardiac myosin light-chain kinase (cMLCK), yet the role(s) played by cMLCK in regulating cardiac function in health and disease remain to be determined. Methods and Results-We found that pressure overload induced by transaortic constriction in wild-type mice reduced phosphorylated MLC2v levels by Ϸ40% and cMLCK levels by Ϸ85%. To examine how a reduction in cMLCK and the corresponding reduction in phosphorylated MLC2v affect function, we generated Mylk3 gene-targeted mice and transgenic mice overexpressing cMLCK specifically in cardiomyocytes. Pressure overload led to severe heart failure in cMLCK knockout mice but not in mice with cMLCK overexpression in which cMLCK protein synthesis exceeded degradation. The reduction in cMLCK protein during pressure overload was attenuated by inhibition of ubiquitinproteasome protein degradation systems.
I n 2006, the overall death rate from cardiovascular disease was 262.5 per 100 000, of which 1 in 8.6 deaths was due to heart failure. During failure, the heart is unable to pump sufficient blood to meet circulatory demand owing to reduced myocardial force development. 1 Pressure development and ejection are achieved by shortening of the minor and long axes of the heart and twisting of the apex (torsion) resulting from differential orientation of ventricular myofibers in roughly 3 layers: inner, mid, and outer. [2] [3] [4] [5] The dynamics of cardiac contraction and relaxation are fundamentally related to actin-myosin interactions, which are initiated by Ca 2ϩ binding to troponin C and relief of inhibition of cross-bridge binding to actin. A range of factors regulate this process and contribute to the adaptation of cardiac function to physiological or pathological stressors, 6 -8 in turn suggesting potential therapeutic strategies for heart failure. 9 -11 
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Myosin is a hexamer composed of 2 heavy chains and 2 pairs of light chains (MLC1 and MLC2) bound to the rod and neck regions of the heavy chain, respectively. Phosphorylation of MLC2v has been shown to potentiate the rate and force of cardiac contraction. [12] [13] [14] [15] [16] Using mutant MLC2v knock-in mice in which 2 phosphorylatable serine residues were mutated to alanine (Ser14/15Ala), our recent study with others demonstrated that phosphorylation increases myosin binding and myosin lever arm stiffness and alters the kinetics of cross-bridge cycling to increase cross-bridge duty ratio (stroke time/cycle time). Furthermore, in addition to the traditional view of Ca 2ϩ -dependent activation of thin filaments, phosphorylated MLC2v can facilitate this process by activating neighboring binding sites on actin. 17 Thus, nonphosphorylatable MLC2v in mice reduced contractility, and reduced phosphorylation of MLC2v has been implicated in human heart disease, in which phosphorylation was reduced from Ϸ30% to 40% in healthy hearts to Ϸ18% of total MLC2v in failing hearts. 18, 19 The predominant kinase for MLC2v, cardiac-specific myosin light-chain kinase (cMLCK), encoded by Mylk3, has been identified as a target of transcription factor Nkx2-5 20 and independently as a gene product that is differentially expressed in failing human hearts. 21 Knockdown of cMLCK in neonatal cardiomyocytes and in zebrafish embryos resulted in abnormal formation of the sarcomere and depressed contraction. 20, 21 A recent study using mice expressing hypomorphic cMLCK confirmed that cMLCK is the predominant MLC2v kinase in the heart and is important for normal cardiac contraction in vivo. 22 Under physiological conditions, the level of MLC2v phosphorylation is relatively constant because of countervailing actions of cMLCK and protein phosphatase 1␤ (also called protein phosphatase 1␦) in association with the myosinbinding phosphatase-target subunit. 23, 24 The level of MLC2v phosphorylation has been shown to vary through the thickness of the murine ventricular wall, being relatively low in the inner layer and high in the outer layer. 13 This gradient has been proposed to be critical for nonuniform contractile properties of the myocytes across the wall, particularly for left ventricular (LV) torsion, the counterclockwise twisting of the LV apex, and the clockwise twisting of the base during systole when viewed from the apex. [3] [4] [5] It has been thought that the gradient is formed by reduction of phosphatase activity in the outer layer. 24, 25 However, the existence of an MLC2v phosphorylation gradient is still controversial, 13, 22 and if it is present, the participation of MLC2v kinase as a determinant of the gradient remains to be clarified.
From these observations, we sought to investigate the role of cMLCK in the heart by determining its transmural expression and its functional roles through the use of loss-or gain-of-function mutations in mice.
Methods

Mouse Models
A conditional null allele of Mylk3 was generated by introducing loxP sites spanning exon 5, which was done through homologous recombination in embryonic stem cells. Mice heterozygous for this Mylk3 allele were bred to mice expressing the ACTB1-Cre transgene, resulting in a germline Mylk3 ϩ/Ϫ allele, followed by crossbreeding to generate Mylk3 Ϫ/Ϫ mice having a mixed genetic background mainly with 129/Sv and C57BL/6. Transgenic mice were generated by injection of hemagglutinin-tagged full-length cMLCK cloned into an ␣-MHC promoter plasmid (kindly provided by J. Robbins). 26 All animal experiments were performed with approval from the University of Florida Institutional Animal Care and Use Committee.
Human Heart Samples
Human heart samples were obtained from the National Human Tissue Resource Center. All protocols were approved by the University of Florida Institutional Review Board.
Additional experimental procedures are described in the onlineonly Data Supplement.
Results
Regional Expression of cMLCK Protein and Phosphorylation of MLC2v in Mouse and Human Hearts
We recently identified an enzyme, cMLCK, that predominantly phosphorylates MLC2v in cardiomyocytes. 20 First, we confirmed that the regional expression of cMLCK and the extent of phosphorylation of MLCv2 (pMLCv2) are almost identical in normal mouse hearts, although labeling of each exhibits nonuniform intensity across transverse tissue sections ( Figure 1A and Figure IA in the online-only Data Supplement). The staining of both was below the level of detection in the absence of cMLCK in Mylk3 Ϫ/Ϫ mice (described later). The specificity of the pMLC2v antibody against pMLC2v was confirmed by Western blotting ( Figure  II in the online-only Data Supplement).
At higher magnification, cMLCK staining was more diffuse in the cytoplasm compared with the striated staining pattern of pMLC2v ( Figure 1B) . Globally, expression of cMLCK and expression of pMLC2v were higher in the right ventricle than in the LV ( Figure 1C and 1D ). In the LV, higher levels of expression were observed in the mid to outer epicardial layers than in the inner endocardial layer at the interventricular septal wall ( Figure 1C -1H). A few layers of myofibers at the surface of the endocardium highly expressed cMLCK and pMLC2v ( Figure 1I-1L ). These cells are Purkinje fibers, which form a ventricular conduction system marked by the presence of the gap junction protein con-nexin40 ( Figure 1M ). In human hearts, levels of cMLCK and pMLC2v were also high in Purkinje fibers that were costained for atrial natriuretic factor ( Figure 1N ). Notably, the antibody against connexin40 was not compatible with the paraffin sections of the human heart.
These data confirm that cMLCK is the predominant kinase for MLC2v, which is highly expressed in the mid and epicardial layers compared with the endocardial layer of the LV, consistent with a previous report, 13 and has even greater expression in the right ventricle and Purkinje fibers.
Reductions in cMLCK and pMLC2v After Pressure Overload
The transmural expression of cMLCK proteins and pMLC2v was quantified by Western blotting of tissue from hearts subjected to pressure overload by transverse aortic constriction (TAC) for 3 months. The endocardial layers significantly thicken after TAC, making them easier to dissect (Figure 2A ). cMLCK expression and MLC2v phosphorylation were higher in the right ventricle than in the LV and were below the level of detection in the endocardial layers ( Figure 2B and 2C and Figure IB in the online-only Data Supplement). Our previous study showed that Ϸ30% of total MLC2v was phosphorylated in normal mouse hearts. 20 In the remaining experiments described (unless otherwise specified), cMLCK expression and pMLC2v expression were examined in the apical third of the heart to minimize variations caused by regional expression of cMLCK. Reductions in cMLCK and pMLC2 were evident as early as 1 week after TAC, by Ϸ85% and Ϸ40%, respectively, compared with control mice ( Figure 2D and 2E).
One week of TAC resulted in ventricular wall thickening without apparent changes in cardiac function (percent fractional shortening [%FS]) or chamber diameters ( Figure 2F and 2G, 1 week). Two weeks of TAC significantly reduced %FS and increased systolic dimensions compared with control values or 1 week of TAC in our experimental conditions ( Figure 2F and 2G). Thus, the functional transition from compensated to decompensated cardiac hypertrophy occurred between 1 and 2 weeks of TAC, shortly after reductions in cMLCK and pMLCv2.
Deletion of Mylk3 Leads to Moderate Abnormalities in Contraction and Conduction Under Basal Conditions
Data from mice with TAC suggest that reduced cMLCK expression and MLC2v phosphorylation may be involved in both chronic and transitional (from compensated to decompensated) cardiac hypertrophy. To examine this possibility mechanistically, we first generated Mylk3 gene-targeted mice and examined whether the absence of cMLCK affects cardiac function. Germline deletion of floxed exon 5 resulted in elimination of the first coding exon of the catalytic domain and a frameshift of the subsequent downstream exons ( Figure  3A and Figure III in the online-only Data Supplement). cMLCK mRNA expression was below the level of detection in Mylk3 Ϫ/Ϫ hearts by Northern blotting with a cDNA probe that recognizes exons 1 through 6 (1266 bp; Figure 3B ). This result is likely attributable to a nonsense-mediated mRNA decay, 27 with targeted cMLCK mRNA containing a prema- , and the endocardial layer (endo) dissected from a TAC heart. C, Unphosphorylated MLC2v and pMLC2v in RV, LV, and papillary muscles dissected from TAC hearts examined with 2-dimensional electrophoresis followed by Western blotting with an anti-MLC antibody. D, Western blotting of cMLCK, pMLC2v, total MLC2v, and GAPDH after 1 week of TAC (lanes 6 -9) and control (lanes 1-5). E, Fold difference of cMLCK, pMLC2v, and total MLC2v normalized to GAPDH with the value without TAC defined as 1. F, Representative images of sequential M-mode ultrasound of a Mylk3 ϩ/ϩ mouse from before operation to 4 weeks of TAC. G, Echocardiographic indexes of Mylk3 ϩ/ϩ mice before and during TAC. Time-dependent effects were not significant in the end-diastolic dimension (EDD), and hazard ratio was found with repeated measure ANOVA. %FS indicates percent LV fractional shortening; IVS, interventricular septum; and ES, end systolic. *PϽ0.05. ) . B, Northern blotting shows that cardiac myosin light-chain ture termination codon. In Mylk3 Ϫ/Ϫ hearts, MLC2v phosphorylation was below the level of detection ( Figure 3C ), consistent with immunostaining in Figure 1A .
Mylk3 Ϫ/Ϫ mice were born at the expected mendelian ratios and survived through adulthood beyond 1.5 years of age. Mylk3 Ϫ/Ϫ hearts were moderately enlarged predominantly along the long axis with increased heart weight at 3 and 6 months of age ( Figure 3D and 3E). Neither cytoarchitectural disarray nor increased interstitial fibrosis was observed ( Figure 3F ). Cardiac contraction assessed with magnetic resonance imaging ( Figure  3G and movies in the online-only Data Supplement) and echocardiography ( Figure IV in the online-only Data Supplement) demonstrated a reduction in ejection fraction and increases in the volume of the LV cavity at both end systole and end diastole. Cardiac torsion was also reduced in Mylk3 Ϫ/Ϫ hearts compared with control mice ( Figure 3G ).
Isolated ventricular cardiomyocytes from adult Mylk3 Ϫ/Ϫ mice were larger than cardiomyocytes from control mice and displayed reductions in contractility and speed of relaxation with no changes in amplitude of the intracellular Ca 2ϩ transient ( Figure 3H and 3I).
In the ventricular conduction system, cMLCK and pMLC2v were present at higher levels than in the rest of the LV ( Figure 1K-1N 
Adaptation to Pressure Overload Requires cMLCK
In contrast to the finding that Mylk3 Ϫ/Ϫ mice showed a moderate reduction in contractility under basal conditions, 3 months of TAC resulted in profound heart failure in these mice, which was associated with increased heart size ( Figure  4A ), decreased survival rate ( Figure 4B ), and increased heart weight/tibial length ( Figure 4C ). Hereafter, heart weight is normalized to tibial length in reports of the results of TAC studies because there is an increase in body weight by accumulation of body fluid owing to profound heart failure after TAC, particularly in Mylk3 Ϫ/Ϫ mice.
Mylk3 Ϫ/Ϫ mice had markedly increased LV dimensions at end diastole and end systole with reduced contractility (Figure 4D and 4E ). LV end-systolic pressure (Ϸ100 mm Hg without TAC) was increased to Ϸ180 mm Hg after TAC in Mylk3 ϩ/ϩ mice but not in Mylk3 Ϫ/Ϫ mice (Ϸ120 mm Hg; Figure 4F and 4G). Instead, Mylk3 Ϫ/Ϫ mice exhibited a marked increase in end-diastolic pressure and reduced rates of contraction (dP/dt) and relaxation (ϪdP/dt). These measurements revealed profound systolic and diastolic dysfunction in Mylk3 Ϫ/Ϫ mice ( Figure 4F and 4G).
One week of TAC did not affect cardiac contractility or chamber dimensions in Mylk3 ϩ/ϩ mice. In contrast, Mylk3 Ϫ/Ϫ mice showed a progressive reduction in %FS and increased end-systolic dimension (Figures 2F, 2G , and 4H and Figure  VI in the online-only Data Supplement). Although cardiac function and heart size differed in Mylk3 Ϫ/Ϫ compared with Mylk3 ϩ/ϩ mice before TAC, Mylk3 Ϫ/Ϫ mice displayed no compensatory response to TAC ( Figure 4H ; before TAC, %FS was reduced 25% compared with Mylk3 ϩ/ϩ mice and fell further 1 week after TAC to Ϸ40%).
Role of cMLCK in Response to 4 Weeks of Swimming Exercise
Besides the hypertrophic response to pressure overload, the heart can exhibit hypertrophic growth as an adaptation to exercise. This adaptation results in an increase in absolute force production by the ventricular wall due at least in part to an increase in the total number of actin-myosin motor units working in parallel. 28 To understand the role of cMLCK in the response of the heart to exercise, 3 month-old Mylk3 Ϫ/Ϫ and Mylk3 ϩ/ϩ mice were subjected to 4 weeks of swim training ( Figure 5A ).
Wild-type mice tolerated 4 weeks of swimming, whereas 25% of Mylk3 Ϫ/Ϫ mice died during or shortly after exercise ( Figure 5B ). Both Mylk3 ϩ/ϩ and surviving Mylk3 Ϫ/Ϫ mice demonstrated an increased ratio of heart weight to body weight ( Figure 5C ); however, exercise failed to improve cardiac contraction, evident as a reduction in %FS in Mylk3 Ϫ/Ϫ mice compared with control Mylk3 ϩ/ϩ ( Figure 5D ) and sedentary Mylk3 Ϫ/Ϫ mice at a similar age from 26% to 19% ( Figure IV in the online-only Data Supplement, 3 months of age). In Mylk3 ϩ/ϩ but not in Mylk3 Ϫ/Ϫ mice, swimming increased pMLC2v to 39% (33% without swimming; Figure 5E ) and increased the expression of cMLCK protein ( Figure 5E and 5F) . These results indicate that cMLCK is the predominant kinase mediating increased MLC2v phosphorylation in response to swim training.
Increased expression of fetal genes such as atrial natriuretic factor and brain natriuretic peptide is often observed in failing hearts but was not seen in sedentary Mylk3 Ϫ/Ϫ mice (no swimming), consistent with moderate cardiac dysfunction without an increase in interstitial fibrosis ( Figure 3F ). Exercise-induced hypertrophy normally does not increase the expression of atrial natriuretic factor and brain natriuretic peptide ( Figure 5G , Mylk3 ϩ/ϩ no swim versus swim). 29, 30 Despite the reduction in %FS in Mylk3 Ϫ/Ϫ mice after exercise, there was no substantial increase in atrial natriuretic factor or brain natriuretic peptide before versus after exercise in Mylk3 Ϫ/Ϫ mice.
Overexpression of cMLCK Protects Against Pressure Overload-Induced Cardiac Dysfunction
Profound heart failure in pressure-overloaded Mylk3 Ϫ/Ϫ mice supports our hypothesis that reduced cMLCK expression and MLC2v phosphorylation are involved in decompensated TAC-induced cardiac hypertrophy. We further examined whether excess cMLCK protects the heart during short-and long-term pressure overloading using a second mouse model that overexpresses cMLCK under the control of an ␣-MHC promoter/enhancer. Among 5 transgenic lines, 3 lines expressed cMLCK relatively homogenously in the LV (data not shown) and were examined further. The level of transgenic protein expression relative to the endogenous cMLCK in nontransgenic mice ranged from 6.5-fold in transgenic line 1 (TG1) to 21-fold in TG2 and TG3 ( Figure 6A ), leading to a moderate increase in pMLC2v from 34% of total MLC2v in nontransgenic to 42% to 50% in the transgenics ( Figure 6B ). Basal cardiac function in the 3 transgenic lines was not statistically different from that in the nontransgenic mice, except for a slight reduction in end-diastolic dimensions in TG3 ( Figure VIIA in the online-only Data Supplement).
One week of TAC reduced transgenic proteins expression, similar to endogenous cMLCK proteins ( Figure 6C ), despite endogenous cMLCK and transgenic cMLCK having different promoter/enhancers, exon-intron structures, and 3Ј poly-A tails. These results suggest that the reduction in cMLCK protein by pressure overload is regulated by posttranscriptional mechanisms.
Although nontransgenic and transgenic mice were subjected to similar degrees of pressure overload ( Figure 6D ), the increase in heart weight (determined by the ratio of heart weight to tibial length) was attenuated in transgenics, including the TG3 line with higher cMLCK expression ( Figure 6D ). Attenuation was accompanied by a parallel reduction in cardiomyocyte cell size and preservation of contractility at 2 and 4 weeks after TAC ( Figure VIIB and VIIC in the online-only Data Supplement). After long-term pressure overload (3 months; similar degree in all groups; Figure VIIIA in the online-only Data Supplement) and reductions in both endogenous and transgenic cMLCK proteins ( Figure VIIIB in the online-only Data Supplement), cardiac function was significantly preserved in the highexpressor TG3 line compared with the nontransgenic mice with respect to contractility and chamber size ( Figure 6E and 6F) , interstitial fibrosis ( Figure 6G ), and apoptosis ( Figure 6H and Figure IX in the online-only Data Supplement).
These results further support our hypothesis that elevated expression of cMLCK protein (6.5-fold-21-fold higher than endogenous) protects the heart against cardiac dysfunction during short-and long-term pressure overload.
Involvement of the Ubiquitin-Proteasome System in cMLCK Protein Degradation
To understand the potential mechanisms underlying the reduction in cMLCK protein during pressure overload, we explored the possible role of the ubiquitin-proteasome system, the major nonlysosomal pathway for intracellular protein degradation. Recently, altered activity of the ubiquitinproteasome system has been emphasized in studies of cardiac hypertrophy. [31] [32] [33] Target proteins are polyubiquitinated by concerted action of 3 enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase) before degradation by the 26S proteasome composed of the 20S catalytic and 19S regulatory cores. [31] [32] [33] Both synthetic and natural proteasome inhibitors block proteasome activity: Synthetic peptide aldehyde such as MG132 mimics proteasome substrates, binds to the proteasome active site, and transiently disrupts its activity. A natural inhibitor, lactacystin, covalently binds to the ␤ subunit of the 20S unit and irreversibly and more specifically blocks its activity. 34 We first examined whether endogenous cMLCK expression was upregulated by 2 different proteasome inhibitors, MG132 ( Figure X in the online-only Data Supplement) and lactacystin ( Figure 7A ). Both inhibitors increased cMLCK expression in cardiomyocytes. Next, mice were treated with lactacystin, MG132, or both MG132 and lactacystin 3 hours before the TAC operation, followed by daily injection of the inhibitors for 1 week. Compared with the 80% reduction in cMLCK protein after 1 week of TAC without proteasome inhibitors ( Figure 7B, lane 1 versus 2) , the addition of proteasome inhibitors attenuated the reduction of cMLCK proteins by 40% to 60% in all 3 groups and was most effective when the 2 inhibitors were used in combination ( Figure 7B) . In contrast to reduced cMLCK expression after TAC, the expression of MLC2v and myosin binding protein C assessed on the same membrane was unchanged with or without TAC ( Figure 7C) . Proteasome inhibitors increased the expression of myosin binding protein C but not MLC2v. Thus, TAC-induced reductions and partial rescue by proteasome inhibitors were observed for cMLCK but not MLC2v or myosin binding protein C.
Third, in the fraction of ubiquitylated proteins enriched by TUBE (tandem ubiquitin binding entity)-conjugated beads from the same amount of heart lysate, cMLCK antibodies preferentially recognized proteins with several different molecular weights in the heart lysate from pressure-overloaded Mylk3 ϩ/ϩ hearts in the presence of proteasome inhibitors ( Figure 7D ).
Substrate specificity of ubiquitin-ligation is determined by E3 ligases. Among Ϸ10 muscle-specific E3 ligases, musclespecific RING finger protein 1 (MuRF1) and atrogin-1/ MAFbx are the most intensively studied muscle-specific E3 ligases 32 and are upregulated in rodent hypertrophic models. 35 Overexpression of E3 ligases, including MuRF1 and atrogin-1, has been shown to promote degradation of target Figure 5 (Continued) . 2-dimensional electrophoresis followed by Western blotting and relative amounts of phosphorylated (p) to total MLC2v. F, Western blotting of cMLCK, pMLC2v, total MLC2v, and GAPDH with or without swimming exercise. Fold difference of cMLCK and pMLC2v normalized to total MLC2v with the value in Mylk3 ϩ/ϩ without swimming exercise defined as 1. G, Real-time reverse transcriptase-polymerase chain reaction demonstrates relative expression of atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) mRNA normalized to ␤-actin mRNA with the value in Mylk3 ϩ/ϩ without swimming exercise defined as 1. *PϽ0.05.
Figure 6.
Overexpression of cardiac myosin light-chain kinase (cMLCK) attenuates pressure overload-induced pathological hypertro-proteins in cultured cardiomyocytes 36, 37 but not cMLCK by adenovirus infection into mouse neonatal cardiomyocytes from Ϸ5 to 20 multiplicities of infection ( Figure 7E and 7F) .
Collectively, these results suggest that ubiquitin-proteasomedependent protein degradation and/or processing participates in the reduction of cMLCK protein resulting from TAC, which was not seen for 2 other proteins and was independent of MuRF1 or atrogin-1 in cultured cardiomyocytes.
Discussion
Potential mechanism(s) underlying the transition from compensated to decompensated heart failure are largely unknown.
In this study, we demonstrated that functional transition from compensated to decompensated hypertrophy occurred between 1 and 2 weeks of TAC. Reduced cMLCK expression and MLC2v phosphorylation occurred as early as 1 week and continuously during TAC, suggesting a role for MLC2v phosphorylation in this transition and under long-term pressure overload. Second, this possibility was examined mechanistically in loss-and gain-of function cMLCK mutant mouse models. TAC led to severe heart failure in Mylk3 Ϫ/Ϫ mice but did not affect cardiac contractility in cMLCKoverexpressing mice when the level of cMLCK expression exceeded that of the normal heart. Third, this process involved ubiquitin-proteasome-dependent protein degradation. Fourth, increased cMLCK expression and MLC2v phosphorylation were observed in exercise-induced cardiac hypertrophy after 4 weeks of swim training in Mylk3 ϩ/ϩ mice with unchanged contractility, whereas an induction of MLC2v phosphorylation was not observed in Mylk3 Ϫ/Ϫ mice, which exhibited 25% mortality and reduced contractility. Collectively, these data demonstrate that reduced cMLCK expression and the consequent reduction of pMLC2 play a pivotal role in mediating the transition from compensated to decompensated hypertrophy. In addition, induction of cMLCK is critical for the cardiac adaptive response to exercise stress, presumably as a result of MLC2v phosphorylation-dependent facilitation of cross-bridge formation, as discussed in our earlier study. 17 Transgenic mice overexpressing cMLCK did not display an obvious cardiac phenotype (based on size or function) under basal conditions even with an Ϸ21-fold increase in expression. After TAC, however, beneficial effects were evident, including maintenance of contractility without fibrosis or apoptotic cell death. Levels of exogenous, transgenically expressed cMLCK protein were also substantially decreased by TAC. Thus, a Ͼ6.5-fold induction of cMLCK under basal conditions causes protein synthesis to exceed degradation during TAC, and the increased levels of cMLCK are sufficient to have a beneficial effect on cardiac function after TAC.
Proteasome inhibitors could attenuate, at least in part, the fall in cMLCK protein after TAC; however, inhibition of proteasomal processing does not necessarily improve cardiac function in rats. 38 The proteasome inhibitor bortezomib is the first approved by the Food and Drug Administration for clinical application. Patients with multiple myeloma treated with bortezomib demonstrated cardiotoxicity, including heart failure, as did normal rats. 39, 40 Thus, a more specific methodology to attenuate cMLCK protein degradation during overloading must be identified. Because substrate specificity is defined by E3 ligases, we reasoned that identification of an E3 ubiquitin-ligase specific for cMLCK might be a step in this direction. However, the 2 best-characterized musclespecific E3 ligases, MuRF1 and atrogin-1, failed to reduce cMLCK expression in cardiomyocytes. Thus, identifying cMLCK-specific E3 ligases and determining how proteasomal processing works on cMLCK, whether by degradation and elimination or a process yielding biological active polypeptide fragments of cMLCK, remain to be accomplished. 41 Exercise is a stressor of the heart resulting in regional adaptive hypertrophy and alterations in contractility and biochemical properties of myocardial proteins. 42 Typically, greater responses to exercise are observed in endocardial than epicardial layers. 42 In this study, swimming increased the expression of cMLCK and phosphorylation of MLC2v. Mylk3 Ϫ/Ϫ mice exhibited cardiac dysfunction in response to long-term exercise and reduced survival compared with control Mylk3 ϩ/ϩ mice. These findings are in contradistinction to the beneficial effects of exercise reported in other genetic mouse models with cardiac dysfunction in which exercise improved cardiac function and/or lifespan. 43, 44 Collectively, this finding suggests that cMLCK plays an essential role by inducing a beneficial adaptation of the heart to exercise, which is consistent with pMLC2v playing a critical role in cardiac adaptation to increased loading of the heart such as that which occurs with regular exercise. 45 We also found that spatial distributions of pMLC2v and cMLCK expression were nearly identical and were neither homogeneous nor simple gradients between the inner and outer layers of the rodent heart. 13 Nonuniform distributions of cMLCK and pMLC2v are consistent with previous observations that the ventricular walls are not homogeneous in terms of size, electrophysiological coupling, or active wall stress under basal conditions. 46 -48 It is possible that expression of cMLCK is related to spatial orientation of fibers and corresponding variations in fiber stress, which may confer to myocytes across the wall variable contractile properties that contribute to LV torsion. [3] [4] [5] 13 In this regard, torsion was substantially reduced in Mylk3 Ϫ/Ϫ and MLC2v (Ser14/15Ala) knock-in mutant mice. 17 cMLCK expression is higher in right ventricular than in LV myocardium, exhibiting an inverse relationship to systolic pressure (Ϸ17 mm Hg in the right ventricle 49 versus Ϸ100 mm Hg in the LV). cMLCK expression in the LV was markedly downregulated as a result of TAC. Furthermore, cMLCK is highly expressed in the specialized cardiomyocytes of the ventricular conduction system, even though the contractile protein content in these cells is substantially less than in contractile myocytes. These results could be interpreted as showing that increased mechanical stress reduces net expression of cMLCK by increasing ubiquitinproteasome activity. It is also possible that cMLCK expres- sion and pMLC2v levels are related to diastolic pressure, decreasing with long-term increases in diastolic pressure as proposed previously. 50 Of course, both active and passive stresses vary within the wall as a function of the radius of curvature, which in turn varies with depth within the wall and position along the base-apex axis. Viewed this way, an inverse relationship between wall stress and cMLCK and pMLC2v expression might provide a regulatory mechanism by which variations in stress are normalized.
With respect to the ventricular conduction system, our observation of high levels of cMLCK expression and pMLC2v in normal mouse and human hearts was unexpected. It seems unlikely that increased cMLCK and pMLC2v would influence the activity of the conduction system, although our experiments do not rule out this possibility.
Our finding of depressed cardiac contraction in a nearly complete absence of MLC2v phosphorylation in our Mylk3 Ϫ/Ϫ mice is consistent with results of a recent study using hypomorphic cMLCK mutant mice. 22 However, our Mylk3 Ϫ/Ϫ mice demonstrated milder cardiac dysfunction without an increase in interstitial fibrosis and only a marginal increase in fetal gene expression, including atrial natriuretic factor and brain natriuretic peptide, under basal conditions. The milder phenotype displayed in our Mylk3 Ϫ/Ϫ mice might be attributed to the absence of Neo R cassettes or to differences in mouse genetic backgrounds and other experimental conditions. 51 A limitation of this study is that cardiac function was different between the mouse models (mutants versus wild type) under basal conditions before being subjected to a cardiac stress. This was particularly true for Mylk3 Ϫ/Ϫ mice. However, because we observed reciprocal phenotypes in mice with constitutively less or more cMLCK, our conclusions appear to be sound.
Conclusions
This study demonstrates that cMLCK plays essential roles in cardiac adaptations to exercise and pressure overload. Development of heart failure under pressure overload is attenuated by greater expression of cMLCK without apparent adverse effects on normal cardiac function in the absence of increased loading. Thus, an increase in the expression of cMLCK or enhancement of its function is a potentially important therapeutic strategy for the treatment of heart failure resulting from pressure overload (ie, hypertensive heart failure).
